Veeva Sys Inc Stock Price, News & Analysis

Veeva Systems (NYSE:VEEV) reported strong fiscal 2026 second quarter results with total revenues of $789.1M, up 17% year-over-year. Subscription services revenues increased 17% to $659.2M. The company achieved notable financial metrics, including non-GAAP operating income of $352.6M (up 26%) and non-GAAP net income of $333.4M (up 25%).

Key developments include the progress of Veeva AI with planned releases starting December, significant Vault CRM Suite milestones with over 100 customers live, and a strategic partnership with IQVIA. The company updated its FY2026 guidance, projecting total revenues between $3,134M and $3,140M.

Veeva Systems (NYSE:VEEV) has announced details for its upcoming R&D and Quality Summit, scheduled for September 3-4 in Boston. The event will bring together over 2,000 life sciences professionals from leading companies including Alnylam, BeOne Medicines, Intercept, Merck, Pfizer, and Sanofi.

A key highlight will be the showcase of Veeva AI, built into the Vault Platform with secure access to data, documents, and workflows. The summit will feature more than 100 sessions focusing on accelerating development, manufacturing processes, and improving trial oversight. Notable case studies include Merck's clinical operations streamlining, FUJIFILM Biotechnologies' global quality management implementation, and Sanofi's study training optimization.

IQVIA (NYSE:IQV) and Veeva Systems (NYSE:VEEV) have announced comprehensive global partnerships in clinical and commercial domains, alongside resolving all pending legal disputes. The long-term agreement enables seamless integration of both companies' software, data, technology, and services.

The partnership encompasses two key areas: Commercial collaboration, establishing master data and third-party access agreements for mutual data usage across platforms, and Clinical integration, with IQVIA joining Veeva's CRO Clinical Data Partner program to leverage the Veeva Clinical Suite for clinical trials execution.

The collaboration aims to enhance customer efficiency by streamlining product integration and accelerating clinical development processes, database builds, study locks, and data delivery.

Veeva Systems (NYSE:VEEV) and IQVIA (NYSE:IQV) have announced comprehensive global partnerships in clinical and commercial domains, alongside resolving all pending legal disputes. The long-term agreement enables seamless integration of both companies' software, data, technology, and services.

The commercial partnership establishes master data and third-party access agreements, allowing mutual data usage across platforms including Veeva Network, Veeva Nitro, and Veeva AI. IQVIA has joined multiple Veeva partner programs to support customer integrations. In the clinical domain, IQVIA's participation in Veeva's CRO Clinical Data Partner program will facilitate clinical trials execution using Veeva's software products, particularly in EDC (Electronic Data Capture) implementations.

Veeva Systems (NYSE:VEEV) released its 2025 MedTech Clinical Benchmark report, revealing key trends in medical technology clinical operations. The study shows that 68% of medtech teams prioritize reducing manual processes in site collaboration, while 56% focus on study quality improvement.

The report highlights significant gaps in technology adoption, with only 14% of large medtechs (>$1B revenue) and 24% of smaller companies having site collaboration tools. Additionally, 72% of organizations plan to invest in AI/ML infrastructure, while 58% will prioritize data collection and cleaning in the coming year.

Key challenges identified include on-time data entry, document exchange, and monitoring compliance, with manual processes (32%), global trial regulation compliance (18%), and inspection readiness (18%) being the top hurdles.

Veeva Systems (NYSE: VEEV) has scheduled its fiscal 2026 second quarter financial results announcement for August 27, 2025, after market close. The company will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the results.

Prepared remarks will be available on Veeva's investor relations website at approximately 1:05 p.m. PT. Investors can access the conference call through registration and follow the webcast on ir.veeva.com. A replay of the webcast will be available following the event.

Veeva Systems (NYSE:VEEV) released its 2025 Medtech Regulatory Affairs Benchmark report, revealing significant challenges in regulatory data quality and processes. The study found that 50% of respondents lack full confidence in their global product registration data, while only 17% rate their regulatory data quality as excellent.

Key findings show that 80% of respondents take a month or longer to prepare 510(k) submissions, with 24% requiring over six months. Only 5% use fully automated time-to-market monitoring, while 67% rely on manual processes. Major operational challenges include administrative burden (61%), siloed processes (49%), and digital tool proficiency (35%).

To address these challenges, 56% of organizations plan to adopt regulatory information management systems, while 52% aim to develop system integrations.

Veeva Systems (NYSE:VEEV) announced that Boehringer Ingelheim, a top 20 biopharma company, will standardize its customer data across more than 100 countries using Veeva OpenData and Veeva Network solutions.

The implementation will provide Boehringer Ingelheim's teams with accurate customer reference data to engage healthcare professionals (HCPs) more effectively and create a foundation for AI scaling. The consolidation to a single comprehensive solution will simplify data management and improve cross-team collaboration through standardized, high-quality customer data access.

The integration with Veeva Vault CRM will be streamlined through native OpenData and Network connections, supporting Boehringer's commercial excellence and AI initiatives.

Veeva Systems (NYSE: VEEV) announced that Merck (NYSE: MRK) has committed to implementing Veeva Vault CRM to support their upcoming product launches across multiple therapeutic areas. The partnership expansion highlights Merck's strategic decision to leverage Vault CRM for enhanced commercial execution.

Vault CRM, part of the Vault CRM Suite, offers deep applications for commercial execution across personal and digital channels, featuring advanced global capabilities to address region-specific business and compliance requirements. This technology adoption comes at a crucial time as Merck prepares for one of its most significant launch periods in company history.